|
|||||
|
|
| Continuation,reduction, or withdrawal of tofacitinib in patients with rheumatoid arthritis achieving sustained disease control: a multicenter,open-label,randomized controlled trial题录 | |
| 作者姓名： | Wang Mengyan Xue Yu Du Fang Ma Lili Lu Liang-jing Jiang Lindi Tao Yi-Li Yang Chengde Shi Hui Liu Honglei Cheng Xiaobing Ye Junna Su Yutong Zhao Dongbao Dai Sheng-Ming Teng Jialin Hu Qiongyi |
| 作者单位： | 1. Department of Rheumatology and Immunology;8. Department of Rheumatology |
| 摘 要： | Background: Rheumatoid arthritis (RA), a chronic systemic autoimmune disease, is characterized by synovitis and progressive damage to the bone and cartilage of the joints, leading to disability and reduced quality of life. This study was a randomized clinical trial comparing the outcomes between withdrawal and dose reduction of tofacitinib in patients with RA who achieved sustained disease control.Methods: The study was designed as a multicenter, open-label, randomized controlled trial. Eligible... |
| 关 键 词： | Tofacitinib Rheumatoid arthritis Withdrawal Dose reduction |